Changing Treatment Paradigms: Hepatitis C Virus in HIV-Infected Patients
- 1 March 2007
- journal article
- review article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 21 (3) , 154-168
- https://doi.org/10.1089/apc.2006.0126
Abstract
The evaluation of hepatic histology and treatment of hepatitis C virus (HCV)/HIV-coinfected patients is rapidly changing. HCV has become an important cause of mortality in HIV-infected patients. Consequently, assessment of liver histology in all coinfected patients is particularly important. The evaluation of hepatic histology is shifting from reliance on the liver biopsy toward noninvasive modalities. Additionally, the importance of HCV-associated morbidity and mortality in HIV-infected patients has prompted increasing numbers of these patients to be HCV treatment candidates. Prospective trials in coinfected patients have reported lower sustained virologic responses compared to HCV-monoinfected patients. Consequently, the numbers of coinfected nonresponders to pegylated interferon/ribavirin continues to increase. Because none of the presently available treatment modalities for pegylated interferon/ribavirin nonresponders are clearly efficacious, management decisions must be individualized. The options include, HCV-specific medications, maintenance therapy, the use of alternative interferon formulations, and observation. HCV-specific agents, particularly protease and polymerase inhibitors, show early promise in HCV-monoinfected individuals. Their use in coinfected patients, however, is likely to be delayed for several years, and they are likely to be used in combination with interferon. Low-dose pegylated interferon, administered in an attempt to slow fibrosis progression (maintenance therapy), is being evaluated in several large prospective trials in monoinfected and coinfected patients. Observation may be best for nonresponders with relatively mild hepatic histology. In summary, HCV treatment will likely follow the example forged by HIV. In the near future, combinations of different drugs will likely be used simultaneously to result in durable viral suppression.Keywords
This publication has 104 references indexed in Scilit:
- Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infectionJournal of Hepatology, 2006
- Definition and management of anemia in patients infected with hepatitis C virusLiver International, 2006
- Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot studyPublished by Elsevier ,2005
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Noninvasive markers of hepatic fibrosis: Are they ready for prime time in the management of HIV/HCV co-infected patients?Journal of Hepatology, 2005
- HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†Hepatology, 2005
- ReplyJournal of Hepatology, 2005
- A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis CHepatology, 2003
- Progression of Chronic Hepatitis C to Liver Fibrosis and Cirrhosis in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency VirusClinical Infectious Diseases, 2003
- Human immunodeficiency virus infection modified the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosisJournal of Hepatology, 1997